Editpep

Executive Summary

Editpep is a preclinical-stage biotechnology company pioneering non-viral delivery of CRISPR-based gene therapies, with an initial focus on central nervous system (CNS) disorders. Founded in 2020 and based in Cambridge, MA, the company's proprietary PERC™ platform delivers CRISPR ribonucleoprotein complexes without viral vectors or lipid nanoparticles, potentially enabling more precise and scalable treatments. Editpep aims to overcome key limitations of current gene editing delivery methods, such as immunogenicity and limited payload capacity, targeting genetic diseases of the brain. While still in early development, the company's approach addresses a critical bottleneck in CRISPR therapeutics, particularly for CNS indications where safe and effective delivery remains challenging. Given its innovative platform and focus on high-unmet-need diseases, Editpep represents an early-stage opportunity with significant potential, albeit with inherent development risk. The company has not publicly disclosed funding details or a specific pipeline timeline, but its technology has attracted attention in the gene editing space.

Upcoming Catalysts (preview)

• Q3 2026Series A or B Financing Round70% success
• Q4 2026IND Filing for Lead CNS Program40% success
• Q4 2026Partnership with Major Pharma or Research Institution50% success